Gilead Sinks After Lung Cancer Drug Fails to Improve Survival

(Bloomberg) -- Gilead Sciences Inc.’s Trodelvy failed to significantly improve survival in a trial of patients with advanced lung cancer, a blow to the targeted treatment that’s in one of the most promising classes in oncology.Most Read from BloombergFlorida Governor DeSantis Drops Out of 2024 Race, Endorses TrumpHong Kong Stocks at 36% Discount Show True Depth of China GloomMorgan Stanley, JPMorgan Say Buy the Dip After Treasury RoutGloom Over China Assets Is Spreading Beyond Battered StocksHed

Related Keywords

London , City Of , United Kingdom , California , United States , New York , Foster City , Merdad Parsey , Daiichi Sankyo , Bloomberg Businessweek , Merck Co , Daiichi Sankyo Co , Abbvie Inc , Immunogen Inc , Astrazeneca , Ambrx Biopharma Inc , Astrazeneca Plc , Johnson , Bloomberg Gilead Sciences Inc , Bloomberg , Medical Officer Merdad Parsey , Gilead Sciences Inc , Lung Cancer , Breast Cancer , Wilead , Bladder Cancer ,